Renal Complications Related to Checkpoint Inhibitors: Diagnostic and Therapeutic Strategies
Open Access
- 30 June 2021
- journal article
- review article
- Published by MDPI AG in Diagnostics
- Vol. 11 (7) , 1187
Abstract
Immune checkpoint inhibitors (ICI) targeting CTLA-4 and the PD-1/PD-L1 axis have unprecedentedly improved global prognosis in several types of cancers. However, they are associated with the occurrence of immune-related adverse events. Despite their low incidence, renal complications can interfere with the oncologic strategy. The breaking of peripheral tolerance and the emergence of auto- or drug-reactive T-cells are the main pathophysiological hypotheses to explain renal complications after ICI exposure. ICIs can induce a large spectrum of renal symptoms with variable severity (from isolated electrolyte disorders to dialysis-dependent acute kidney injury (AKI)) and presentation (acute tubule-interstitial nephritis in >90% of cases and a minority of glomerular diseases). In this review, the current trends in diagnosis and treatment strategies are summarized. The diagnosis of ICI-related renal complications requires special steps to avoid confounding factors, identify known risk factors (lower baseline estimated glomerular filtration rate, proton pump inhibitor use, and combination ICI therapy), and prove ICI causality, even after long-term exposure (weeks to months). A kidney biopsy should be performed as soon as possible. The treatment strategies rely on ICI discontinuation as well as co-medications, corticosteroids for 2 months, and tailored immunosuppressive drugs when renal response is not achieved.Keywords
This publication has 67 references indexed in Scilit:
- Fulminant Myocarditis with Combination Immune Checkpoint BlockadeNew England Journal of Medicine, 2016
- Clinicopathological features of acute kidney injury associated with immune checkpoint inhibitorsKidney International, 2016
- Urinary soluble CD163 level reflects glomerular inflammation in human lupus nephritisNephrology Dialysis Transplantation, 2016
- Severe acute interstitial nephritis after combination immune-checkpoint inhibitor therapy for metastatic melanomaClinical Kidney Journal, 2016
- Management of immune checkpoint blockade dysimmune toxicities: a collaborative position paperAnnals of Oncology, 2015
- Effect of maintenance immunosuppressive drugs on virus pathobiology: evidence and potential mechanismsReviews in Medical Virology, 2012
- Clinical Pharmacokinetics of Therapeutic Monoclonal AntibodiesClinical Pharmacokinetics, 2010
- Phase I Study of Single-Agent Anti–Programmed Death-1 (MDX-1106) in Refractory Solid Tumors: Safety, Clinical Activity, Pharmacodynamics, and Immunologic CorrelatesJournal of Clinical Oncology, 2010
- Anti-CTLA4 Antibody–Induced Lupus NephritisNew England Journal of Medicine, 2009
- PD-L1 is expressed by human renal tubular epithelial cells and suppresses T cell cytokine synthesisClinical Immunology, 2005